Morgan Stanley Axcella Health Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.22 - $0.46 $5,523 - $11,549	25,108 New	25,108 $5,000
Q3 2022 Nov 14, 2022	SELL	$1.62 - $2.73 $1,125 - $1,897	-695 Reduced 99.29%	5 $0
Q2 2022 Oct 27, 2022	SELL	$1.41 - $2.77 $1,335 - $2,623	-947 Reduced 57.5%	700 $1,000
Q2 2022 Aug 15, 2022	SELL	$1.41 - $2.77 $1,335 - $2,623	-947 Reduced 57.5%	700 $1,000
Q1 2022 Oct 27, 2022	BUY	$1.58 - $2.82 $1,496 - $2,670	947 Added 135.29%	1,647 $4,000
Q1 2022 May 13, 2022	SELL	$1.58 - $2.82 $109 - $194	-69 Reduced 4.02%	1,647 $4,000
Q4 2021 Feb 14, 2022	SELL	$2.06 - $3.61 $61 - $108	-30 Reduced 1.72%	1,716 $3,000
Q3 2021 Nov 15, 2021	BUY	$2.98 - $4.31 $5,203 - $7,525	1,746 New	1,746 $5,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.